Timothy J. Kamp

Professor - Medicine; Co-director - Stem Cell and Regenerative Medicine Center

tjk@medicine.wisc.edu

Phone: (608) 263-1172, (608) 263-1532

ORGAN SYSTEM/DISEASE FOCUS - Cardiac, ischemic heart disease, heart failure, arrhythmias
ALIGNED RESEARCH FOCUS - Cardiogenesis from embryonic stem cells

 

Address: 8459 WIMR II – 1111 Highland Ave. – Madison, WI 53705
More information: Dr. Kamp’s Department of Medicine Home Page

 

News Releases:

PubMed

Education

B.S. magna cum laude, 1978-1982, University of Notre Dame, Notre Dame, Indiana, Preprofessional Studies
M.D. cum laude, 1982-1989 University of Chicago, Pritzker School of Medicine, Chicago, Illinois
Ph.D., 1982-1989, University of Chicago, Department of Pharmacological & Physiological Sciences
Internal Medicine Resident, 1989-1991, Osler Medical Service, Johns Hopkins Hospital, Baltimore, MD
Cardiology Fellow, 1991-1996, Johns Hopkins Hospital, Baltimore, MD

Research

Our research focuses on embryonic stem cells (ESCs) and their applications to cardiovascular research and potentially cardioregenerative medicine.  Our initial work with human ESCs demonstrated that these cells differentiate in embryoid bodies to form spontaneously contracting cardiomyocytes.  Electrophysiological characterization of the hESC-derived cardiomyocytes revealed that different types of cardiomyocytes differentiate including atrial, ventricular and nodal type cells.  Current research is focused on understanding cardiogenesis in the ES cell system and harnessing this process to efficiently obtain defined populations of hESC-derived cardiomycytes.  The human cardiomyocytes obtained from hESCs provide a powerful system to create disease models and to evaluate the cellular electrophysiological and functional properties of human cardiomyocytes at different stages of development.  Other projects in the laboratory examine the use of ESCs and their derivatives in cellular therapies for heart disease.  Myocardial infarction models in mice and large animals have been developed to pilot cellular therapies first employing mouse ESCs and derivatives.  Our initial studies have provided proof of principal evidence that mouse ESCs can induce regeneration in infarcted mouse heart.  Ongoing research focuses on identifying optimal cellular populations derived from ESCs for cardiac therapy, determining the best delivery strategies, and overcoming challenges related to immune rejection of allogeneic cells.

Representative Publications 

  • Feng L, Kamp TJ. (2017) Electrotaxis leads the way. Heart Rhythm. 2017 Nov;14(11):1693-1694.
  • Skelton RJP, Kamp TJ, Elliott DA, Ardehali R. (2017) Biomarkers of Human Pluripotent Stem Cell-Derived Cardiac Lineages. Trends Mol Med. 2017 Jul;23(7):651-668. Review
  • Schaefer JA, Guzman PA, Riemenschneider SB, Kamp TJ, Tranquillo RT. (2017) A cardiac patch from aligned microvessel and cardiomyocyte patches. J Tissue Eng Regen Med. 2017 Sep 5. doi: 10.1002/term.2568. [Epub ahead of print]
  • Yanamandala M, Zhu W, Garry DJ, Kamp TJ, Hare JM, Jun HW, Yoon YS, Bursac N, Prabhu SD, Dorn GW 2nd, Bolli R, Kitsis RN, Zhang J. (2017) Overcoming the Roadblocks to Cardiac Cell Therapy Using Tissue Engineering. J Am Coll Cardiol. 2017 Aug 8;70(6):766-775.  Review
  • Raval, A., T. Kamp and L. Hogle  Cellular Therapies for Heart Disease: Unveiling the Ethical and Public Policy Challenges. 2007. J of Molecular & Cellular Cardiology. doi:10.1016/j.yjmcc.2007.11.005